University of South Alabama Mitchell Cancer Institute — Mobile, Alabama

Public research footprint of University of South Alabama Mitchell Cancer Institute, compiled from the ClinicalTrials.gov public registry.

129

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Locally Advanced Malignant Solid Neoplasm · Recurrent Ovarian Carcinoma · Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma · Recurrent Malignant Female Reproductive System Neoplasm

Recently updated registry entries

NCT03258554 — Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally… (Completed)
NCT06952504 — A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… (Recruiting)
NCT05554328 — Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at University of South Alabama Mitchell Cancer Institute?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.